Innate Pharma to present Nectin-4 Antibody Drug Conjugate IPH45 preclinical data at AACR 2024
First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Innate Pharma announces its participation to upcoming investor conference
Number of shares and voting rights of Innate Pharma as of January 1, 2024
Innate Pharma strengthens leadership and appoints two new members to its Executive Board
Innate Pharma announces U.S. FDA lifts partial clinical hold on lacutamab clinical program
Innate Pharma Announces Licensing Of A Fourth Natural Killer Cell Engager In Oncology To Sanofi
Innate Pharma Announces Leadership Change
Innate Pharma shares efficacy and safety Phase 1 /2 results of NK Cell Engager SAR443579 / IPH6101 developed by Sanofi at ASH 2023
Innate Pharma presents positive results from TELLOMAK Phase 2 study with lacutamab in patients with Sézary syndrome at ASH 2023
